{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"Tumor assessment was performed every 8 weeks until disease progression. Objective response rate was defined as the percentage of patients who achieved a complete response (CR) or a partial response (PR) according to International Workshop Response Criteria (IWC) 2014 criteria and assessed by an Independent Overall Efficacy Review Committee (IOERC).\n\nCR: Target nodes/nodal masses must regress to \\<1.5 cm in longest transverse diameter of a lesion (LDi), no extralymphatic sites of disease, nonmeasured lesion is absent, disappearance of spleen or liver enlargement, no new lesions, no bone marrow (BM) involvement.\n\nPR: ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites, nonmeasured lesions is absent/normal, regressed, but no increase, spleen must have regressed by \\>50% in length beyond normal, no new lesions.","groups":[{"description":"HBI-8000 tablets","id":"OG000","title":"HBI-8000"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The per-protocol analysis set (PPS) included subjects meeting all eligibility criteria who have completed Cycle 1 treatment. For subjects who developed clinical PD and discontinued study treatment during Cycle 1 without significant deviation from protocol, they will be included in the PPS. It should be noted that the PPS includes subjects who discontinued within Cycle 1 due to clinical PD without imaging studies to assess disease status.","reportingStatus":"POSTED","timeFrame":"Up to approximately 47 months.","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}